WO2010094622A1 - 3, 3' -spiroindolinone derivatives as anticancer agents - Google Patents
3, 3' -spiroindolinone derivatives as anticancer agents Download PDFInfo
- Publication number
- WO2010094622A1 WO2010094622A1 PCT/EP2010/051757 EP2010051757W WO2010094622A1 WO 2010094622 A1 WO2010094622 A1 WO 2010094622A1 EP 2010051757 W EP2010051757 W EP 2010051757W WO 2010094622 A1 WO2010094622 A1 WO 2010094622A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- chloro
- phenyl
- indole
- dione
- racemic
- Prior art date
Links
- 0 C*([C@@]([C@]([C@@]([C@@]1C)c2cccc(N)c2)(C(*c2c3)=O)c2ccc3N)C(C)=C)C1=O Chemical compound C*([C@@]([C@]([C@@]([C@@]1C)c2cccc(N)c2)(C(*c2c3)=O)c2ccc3N)C(C)=C)C1=O 0.000 description 2
- SLSYLBGLYWQGQO-GZTJUZNOSA-N CC(C)(C)OC(C(C)(C)Oc(cc1)c(/C=C(\c(c(N2)c3)ccc3Cl)/C2=O)cc1Cl)=O Chemical compound CC(C)(C)OC(C(C)(C)Oc(cc1)c(/C=C(\c(c(N2)c3)ccc3Cl)/C2=O)cc1Cl)=O SLSYLBGLYWQGQO-GZTJUZNOSA-N 0.000 description 1
- NQDUMZSYXOKRSL-OVCLIPMQSA-N CC(C)(c(c(N1C2=O)c(cc3)/C2=C\CCCc2cccnc2)c3Cl)OC1=O Chemical compound CC(C)(c(c(N1C2=O)c(cc3)/C2=C\CCCc2cccnc2)c3Cl)OC1=O NQDUMZSYXOKRSL-OVCLIPMQSA-N 0.000 description 1
- GZJXWUSBZAICIP-CTNGQTDRSA-N CC([C@H]([C@@](c(c(N1)c2)ccc2Cl)(C1=O)C(c1cccc(Cl)c1)=C1)NC1=O)=C Chemical compound CC([C@H]([C@@](c(c(N1)c2)ccc2Cl)(C1=O)C(c1cccc(Cl)c1)=C1)NC1=O)=C GZJXWUSBZAICIP-CTNGQTDRSA-N 0.000 description 1
- OPGMOLVRYJITBG-LHHJGKSTSA-N O=C1Nc2cc(Cl)ccc2/C1=C\CCc1cccnc1 Chemical compound O=C1Nc2cc(Cl)ccc2/C1=C\CCc1cccnc1 OPGMOLVRYJITBG-LHHJGKSTSA-N 0.000 description 1
- XILJTCQMJSVCKW-PXJZQJOASA-N O=C1Nc2cc(Cl)ccc2[C@@]1([C@@H](c1cc(Cl)ccc1OC1CCOCC1)N1)C(c2cccc(F)c2)=CC1=O Chemical compound O=C1Nc2cc(Cl)ccc2[C@@]1([C@@H](c1cc(Cl)ccc1OC1CCOCC1)N1)C(c2cccc(F)c2)=CC1=O XILJTCQMJSVCKW-PXJZQJOASA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the present invention relates to analogues of spiroindolinones having the formula I
- the compounds have utility as antiproliferative agents, especially, as anticancer agents.
- p53 is a tumor suppresser protein that plays a central role in protection against development of cancer. It guards cellular integrity and prevents the propagation of permanently damaged clones of cells by the induction of growth arrest or apoptosis.
- p53 is a transcription factor that can activate a panel of genes implicated in the regulation of cell cycle and apoptosis.
- p53 is a potent cell cycle inhibitor which is tightly regulated by MDM2 at the cellular level. MDM2 and p53 form a feedback control loop. MDM2 can bind p53 and inhibit its ability to transactivate p53-regulated genes. In addition, MDM2 mediates the ubiquitin- dependent degradation of p53.
- MDM2 can activate the expression of the MDM2 gene, thus raising the cellular level of MDM2 protein.
- This feedback control loop insures that both MDM2 and p53 are kept at a low level in normal proliferating cells.
- MDM2 is also a cofactor for E2F, which plays a central role in cell cycle regulation.
- MDM2 The ratio of MDM2 to p53 (E2F) is dysregulated in many cancers. Frequently occurring molecular defects in the pl6INK4/pl9ARF locus, for instance, have been shown to affect MDM2 protein degradation. Inhibition of MDM2-p53 interaction in tumor cells with wild-type p53 should lead to accumulation of p53, cell cycle arrest and/or apoptosis. MDM2 antagonists, therefore, can offer a novel approach to cancer therapy as single agents or in combination with a broad spectrum of other antitumor therapies. The feasibility of this strategy has been shown by the use of different macromolecular tools for inhibition of MDM2-p53 interaction (e.g. antibodies, antisense oligonucleotides, peptides). MDM2 also binds E2F through a conserved binding region as p53 and activates E2F-dependent transcription of cyclin A, suggesting that MDM2 antagonists might have effects in p53 mutant cells.
- the present invention provides spiroindolinone derivatives which are small molecule inhibitors of the MDM2-p53 interaction.
- compounds of the present invention are shown to inhibit the interaction of MDM2 protein with a p53-like peptide.
- these compounds demonstrate mechanistic activity. Incubation of cancer cells with wild-type p53 leads to accumulation of p53 protein, induction of p53-regulated p21 gene, and cell cycle arrest in Gl and G2 phase, resulting in potent antiproliferative activity against wild-type p53 cells in vitro. In contrast, these activities were not observed in cancer cells with mutant p53 at comparable compound concentrations. Therefore, the activity of MDM2 antagonists is likely linked to its mechanism of action. These compounds can be potent and selective anticancer agents.
- the present invention relates to spiroindolinones of the formula
- X is selected from the group consisting of hydrogen, halogen, cyano, nitro, ethynyl, cyclopropyl, methyl, ethyl, isopropyl, methoxy and vinyl,
- Y is hydrogen, hydroxyl, or fluorine
- R 1 is selected from the group consisting of lower alkenyl, substituted lower alkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkenyl and substituted cycloalkenyl and
- R 2 is selected from the group consisting of aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycle, substituted heterocycle, cycloalkenyl and substituted cycloalkenyl or a pharmaceutically acceptable salt or ester thereof.
- X is selected from the group consisting of hydrogen, halogen, cyano, nitro, ethynyl, cyclopropyl, methyl, ethyl, isopropyl, methoxy, and vinyl,
- Y is hydrogen, hydroxyl, or fluorine
- R 1 is selected from the group consisting of lower alkenyl, substituted lower alkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkenyl and substituted cycloalkenyl and
- R 2 is selected from the group consisting of aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycle, substituted heterocycle, cycloalkenyl and substituted cycloalkenyl or a pharmaceutically acceptable salt or ester thereof.
- R 2 is a substituted phenyl or substituted heteroaryl with the substituted phenyl or substituted heteroaryl selected from group consisting of: -A-
- R is selected from the group consisting of lower alkenyl, substituted lower alkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkenyl and substituted cycloalkenyl or a pharmaceutically acceptable salt or ester thereof.
- Most preferred compounds are those of the formula: racemic (2'R,3R)-6-chloro-4'-(3-chloro-phenyl)-2'-(5-fluoro-2-methyl-phenyl)-r,3'- dihydrospiro[3H-indole-3,3'(2'H)-pyridine]-2,6'(lH)-dione; chiral (2'R,3R)-6-chloro-4'-(3-chloro-phenyl)-2'-(5-fiuoro-2-methyl-phenyl)-l ',3'- dihydrospiro[3H-indole-3,3'(2'H)-pyridine]-2,6'(lH)-dione; racemic (2'R,3R)-6-chloro-4'-(3-chloro-phenyl)-2'-(5-fluoro-2-methyl-phenyl)-5-hydroxy- l ',3'-d
- a benzodioxyl group halogen, hydroxy, CN, CF3, NH 2 , N(H, lower-alkyl), N(lower-alkyl)2, amino carbonyl, carboxy, NO 2 , lower-alkoxy, thio-lower-alkoxy, lower-alkylsufonyl, aminosulfonyl, lower-alkylcarbonyl, lower-alkylcarbonyloxy, lower-alkoxycarbonyl, lower-alkyl-carbonyl-NH, fluoro-lower-alkyl, fluoro-lower-alkoxy, lower-alkoxy-carbonyl-lower-alkoxy, carboxy-lower-alkoxy, carbamoyl- lower-alkoxy, hydroxy-lower-alkoxy, NH 2 -lower-alkoxy, N(H, lower-alkyl)-lower-alkoxy, N(lower-alkyl) 2 -lower-alk
- alkyl, alkenyl, alkynyl or similar groups are linked with both ends to the same moiety, cyclic structures may result, where two hydrogens of said moiety are being replaced by the two ends of the alkyl, alkenyl, alkynyl or similar group, thus creating cyclic structures, such as, tetralin, macrocycles or spiro compounds.
- alkyl refers to straight- or branched-chain saturated hydrocarbon groups having from 1 to about 20 carbon atoms. In certain embodiments, alkyl substituents may be lower alkyl substituents.
- lower alkyl refers to alkyl groups having from 1 to 8 carbon atoms, and in certain embodiments from 1 to 4 carbon atoms.
- alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl, t-butyl, n-pentyl, and s-pentyl.
- cycloalkyl is intended to refer to any stable monocyclic or polycyclic system which consists of carbon atoms only, any ring of which being saturated
- cycloalkenyl is intended to refer to any stable monocyclic or polycyclic system which consists of carbon atoms only, with at least one ring thereof being partially unsaturated.
- cycloalkyls include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl, cyclooctyl, bicycloalkyls, including bicyclooctanes such as [2.2.2]bicyclooctane or [3.3.0]bicyclooctane, bicyclononanes such as [4.3.0]bicyclononane, and bicyclodecanes such as [4.4.0]bicyclodecane (decalin), or spiro compounds.
- cycloalkenyls include, but are not limited to, cyclopentenyl or cyclohexenyl.
- alkenyl as used herein means an unsaturated straight-chain or branched aliphatic hydrocarbon group containing one double bond and having 2 to 8, preferably 2 to 6 carbon atoms.
- alkenyl group examples include vinyl (ethenyl), allyl, isopropenyl, 1- propenyl, 2-methyl-l-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 2-ethyl-l-butenyl, 3-methyl-2- butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 4-methyl-3-pentenyl, 1-hexenyl, 2- hexenyl, 3-hexenyl, 4-hexenyl and 5-hexenyl.
- alkynyl as used herein means an unsaturated straight-chain or branched aliphatic hydrocarbon group containing one triple bond and having 2 to 6, preferably 2 to 4 carbon atoms.
- alkynyl group examples include ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl, 1-pentynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 1-hexynyl, 2-hexynyl, 3- hexynyl, 4-hexynyl and 5-hexynyl.
- halogen as used in the definitions means fluorine, chlorine, iodine or bromine, preferably fluorine and chlorine.
- Aryl means a monovalent, monocyclic or bicyclic, aromatic carbocyclic hydrocarbon radical, preferably a 6-10 member aromatic ring system. Preferred aryl groups include, but are not limited to, phenyl, naphthyl, tolyl, and xylyl.
- Heteroaryl means an aromatic heterocyclic ring system containing up to two rings.
- Preferred heteroaryl groups include, but are not limited to, thienyl, furyl, indolyl, pyrrolyl, pyridinyl, pyrazinyl, oxazolyl, thiaxolyl, quinolinyl, pyrimidinyl, imidazole and tetrazolyl.
- aryl or heteroaryl which are bicyclic it should be understood that one ring may be aryl while the other is heteroaryl and both being substituted or unsubstituted.
- Heterocycle means a substituted or unsubstituted 5 to 8 membered, mono- or bicyclic, aromatic or non-aromatic hydrocarbon, wherein 1 to 3 carbon atoms are replaced by a hetero atom selected from nitrogen,oxygen or sulfur atom. Examples include pyrrolidin-2-yl; pyrrolidin-3-yl; piperidinyl; morpholin-4-yl and the like.
- Hetero atom means an atom selected from N, O and S.
- Alkoxy, alkoxyl or lower alkoxy refers to any of the above lower alkyl groups attached to an oxygen atom.
- Typical lower alkoxy groups include methoxy, ethoxy, isopropoxy or propoxy, butyloxy and the like.
- Further included within the meaning of alkoxy are multiple alkoxy side chains, e.g. ethoxy ethoxy, methoxy ethoxy, methoxy ethoxy ethoxy and the like and substituted alkoxy side chains,e.g., dimethylamino ethoxy, diethylamino ethoxy, dimethoxy- phosphoryl methoxy and the like.
- “Pharmaceutically acceptable,” such as pharmaceutically acceptable carrier, excipient, etc., means pharmacologically acceptable and substantially non-toxic to the subject to which the particular compound is administered.
- “Pharmaceutically acceptable salt” refers to conventional acid-addition salts or base- addition salts that retain the biological effectiveness and properties of the compounds of the present invention and are formed from suitable non-toxic organic or inorganic acids or organic or inorganic bases.
- Sample acid-addition salts include those derived from inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, sulfamic acid, phosphoric acid and nitric acid, and those derived from organic acids such as p-toluenesulfonic acid, salicylic acid, methanesulfonic acid, oxalic acid, succinic acid, citric acid, malic acid, lactic acid, fumaric acid, trifluoro acetic acid and the like.
- Sample base-addition salts include those derived from ammonium, potassium, sodium and, quaternary ammonium hydroxides, such as for example, tetramethylammonium hydroxide.
- Chemical modification of a pharmaceutical compound (i.e. drug) into a salt is a technique well known to pharmaceutical chemists to obtain improved physical and chemical stability, hygroscopicity, flowability and solubility of compounds. See, e.g., Ansel et ah, Pharmaceutical Dosage Forms and Drug Delivery Systems (6th Ed. 1995) at pp. 196 and 1456-1457.
- the compounds of formula I as well as their salts have at least one asymmetric carbon atom and therefore may be present as racemic mixtures or different stereoisomers.
- the various isomers can be isolated by known separation methods, e.g., chromatography.
- the invention includes all stereoisomers.
- the compounds of the present invention are useful in the treatment or control of cell proliferative disorders, in particular oncological disorders. These compounds and formulations containing said compounds may be useful in the treatment or control of solid tumors, such as, for example, breast, colon, lung and prostate tumors.
- a therapeutically effective amount of a compound in accordance with this invention means an amount of compound that is effective to prevent, alleviate or ameliorate symptoms of disease or prolong the survival of the subject being treated. Determination of a therapeutically effective amount is within the skill in the art.
- the therapeutically effective amount or dosage of a compound according to this invention can vary within wide limits and may be determined in a manner known in the art. Such dosage will be adjusted to the individual requirements in each particular case including the specific compound(s) being administered, the route of administration, the condition being treated, as well as the patient being treated. In general, in the case of oral or parenteral administration to adult humans weighing approximately 70 Kg, a daily dosage of about 10 mg to about 10,000 mg, preferably from about 200 mg to about 1,000 mg, should be appropriate, although the upper limit may be exceeded when indicated. The daily dosage can be administered as a single dose or in divided doses, or for parenteral administration, it may be given as continuous infusion.
- Formulations of the present invention include those suitable for oral, nasal, topical (including buccal and sublingual), rectal, vaginal and/or parenteral administration.
- the formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy.
- the amount of active ingredient which can be combined with a carrier material to produce a single dosage form will vary depending upon the host being treated, as well as the particular mode of administration.
- the amount of active ingredient which can be combined with a carrier material to produce a single dosage form will generally be that amount of a formula I or II or III compound which produces a therapeutic effect. Generally, out of one hundred percent, this amount will range from about 1 percent to about ninety-nine percent of active ingredient, preferably from about 5 percent to about 70 percent, most preferably from about 10 percent to about 30 percent.
- Methods of preparing these formulations or compositions include the step of bringing into association a compound of the present invention with the carrier and, optionally, one or more accessory ingredients.
- the formulations are prepared by uniformly and intimately bringing into association a compound of the present invention with liquid carriers, or finely divided solid carriers, or both, and then, if necessary, shaping the product.
- Formulations of the invention suitable for oral administration may be in the form of capsules, cachets, sachets, pills, tablets, lozenges (using a flavored basis, usually sucrose and acacia or tragacanth), powders, granules, or as a solution or a suspension in an aqueous or non- aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as pastilles (using an inert base, such as gelatin and glycerin, or sucrose and acacia) and/or as mouth washes and the like, each containing a predetermined amount of a compound of the present invention as an active ingredient.
- a compound of the present invention may also be administered as a bolus, electuary or paste.
- Effective amount means an amount that is effective to prevent, alleviate or ameliorate symptoms of disease or prolong the survival of the subject being treated.
- IC50 refers to the concentration of a particular compound required to inhibit 50% of a specific measured activity. IC50 can be measured, inter alia, as is described subsequently.
- “Pharmaceutically acceptable ester” refers to a conventionally esterif ⁇ ed compound of formula I having a carboxyl group or hydroxy group, which esters retain the biological effectiveness and properties of the compound of formula I and are cleaved in vivo (in the organism) to the corresponding active carboxylic acid or alcohol respectively.
- an appropriately selected aldehyde I can be reacted with lithium hexamethyldisilamide, chlorotrialkylsilane and a chloroacyl chloride in a one-pot, multi-steps manner to generate 2-aza-l,3-butadiene II (Scheme I) and were used as a crude product.
- Scheme 2 The appropriately selected aldehyde I are either commercially available or can be synthesized by well-established multiple literature methods.
- 6-substituted or 5,6-disubstituted oxindole III starting materials are either commercially available or prepared according to literature methods, for examples, from the corresponding 4- substituted 2-nitro-fluoro or chlorobenzene according to Kraynack, E. A.; Dalgard, J. E.; Gaeta, F. C. A. Tetrahedron Letters, 1998, 39, 7679 - 7682, or EP153818 for S-fiuro- ⁇ -chlorooxindole.
- Oxindole III can be reacted with an appropriately substituted aldehyde in the presence of base under heated condition in either a protic solvent to give intermediate IV.
- the commonly used base is either pyrrolidine or piperidine.
- Intermediate IV can be converted to intermediate V via a protection reaction using di-tert-butyl dicarbonate and 4-dimethylpyridine or 4- dimethylpyridine and triethylamine combines as the base(s).
- Intermediate V can then be reacted with 2-aza-l,3-butadiene II in toluene or xylene under heating from 110 0 C to 160 0 C and anhydrous condition followed by treatment with trifluoro acetic acid in dichloromethane at room temperature to afford a racemic mixture of siproindolinone VI and VI'.
- a further embodiment of the present invention relates to a process for the synthesis of a compound of formula (I) according to general schemes 1 to 2.
- the reaction mixture was filtered through a short pad of celite gel and washed with ethyl acetate. The filtrate was concentrated. The residue was dissolved in dichloromethane (10 mL) and trifluoroactic acid (10 mL) was added. After the reaction mixture was stirred at room temperature for 1 h, the mixture was concentrated. The residue was partitioned between saturated NaHCO 3 solution and ethyl acetate. The aqueous layer was extracted with ethyl acetate. The combined extracts were dried over Na 2 SO 4 and concentrated.
- 6-chlorooxindole (3.61 g, 21.5 mmol) was reacted with 3-fluoro-benzaldehyde (Aldrich, 2.26 mL, 21.5 mmol) and piperdine (2.12 mL, 21.5 mmol) in methanol to give 6-chloro-3-[l-(3-fluoro-phenyl)-methylidene]-l,3-dihydro- indol-2-one as a yellow solid (Yield 4.5 g, 76%).
- 3-fluoro-benzaldehyde Aldrich, 2.26 mL, 21.5 mmol
- piperdine (2.12 mL, 21.5 mmol
- racemic (2'R, 3R, 4'S, 5'S)-5',6- dichloro-4'-[5-chloro-2-(2-hydroxy-ethoxy)-phenyl]-2'-(5-fluoro-2-methyl-phenyl) spiro[3H- indole-3,3'-piperidine]-2,6'(lH)-dione in Example 20 (0.2 g, 0.35 mmol) was heated with DBU in toluene to give racemic (2'R, 3R)-6-chloro-2'-[5-chloro-2-(2-hydroxy-ethoxy)-phenyl]-4'-(5- fluoro-2-methyl-phenyl)-r,3'-dihydrospiro[3H-indole-3,3'-pyridine]-2,6'(lH)-dione as a light yellow solid (Yield 30 mg, 16%).
- racemic (2'R, 3R, 4'S, 5'S)-5',6- dichloro-4'-(3-chloro-phenyl)-2'-isopropenyl spiro[3H-indole-3,3 '-piperidine]-2,6'(lH)-dione in Example 24 (0.52 g, 0.69 mmol) was heated with DBU in toluene to give racemic (2'R, 3R)-6- chloro-4'-(3-chloro-phenyl)-2'-isopropenyl-r,3'-dihydrospiro[3H-indole-3,3 '-pyridine]- 2,6'(lH)-dione as a yellow solid (Yield 50 mg, 18%).
- E/Z-6-chloro-3-(3-chloro- benzylidene)-5-fluoro-l,3-dihydro-indol-2-one (0.45 g, 1.46 mmol) was reacted with di-tert- butyl-dicarbonate (0.4 g, 1.83 mmol) (Aldrich), triethyl amine (0.5 g, 4.95 mmol) and 4- dimethylaminopyridine (5 mg) in dichloromethane (30 mL) to give E/Z-6-chloro-3-(3-chloro- benzylidene)-5-fluoro-2-oxo-2,3-dihydro-indole-l-carboxylic acid tert-butyi ester as a yellow solid (Yield: 0.6 g, 100%).
- racemic (2'R, 3R, 4'S, 5'S)-5',6- dichloro-4'-(3-chloro-phenyl)-5-fluoro-2'-(5-fluoro-2-methyl-phenyl) spiro[3H-indole-3,3'- piperidine]-2,6'(lH)-dione in Example 27 (0.6 g, 1.14 mmol) was heated with DBU in toluene to give racemic (2'R,3R)-6-chloro-4'-(3-chloro-phenyl)-5-fluoro-2'-(5-fluoro-2-methyl-phenyl)- l ',3'-dihydrospiro[3H-indole-3,3'(2'H)-pyridine]-2,6'(lH)-dione as a yellow solid (Yield 40 mg, 7%).
- E/Z-6-chloro-3-furan-3-ylmethylene- l,3-dihydro-indol-2-one (1.45 g, 5.9 mmol) was reacted with di-t ⁇ t-butyl-dicarbonate (1.54 g, 7.08 mmol) (Aldrich), and 4-dimethylaminopyridine (25 mg) in dichloromethane to give E/Z-6- chloro-S-furan-S-ylmethylene-l-oxo-l ⁇ -dihydro-indole-l-carboxylic acid tert-butyl ester as a yellow solid (Yield: 1.6 g, 79%).
- E/Z-6-chloro-3-thiophen-3- ylmethylene-l,3-dihydro-indol-2-one (2.4 g, 9.17 mmol) was reacted with di-tert-buty ⁇ - dicarbonate (2.4 g, 11 mmol) (Aldrich), and 4-dimethylaminopyridine (45 mg) in dichloromethane to give E/Z-6-chloro-2-o xo-3-thiophen-3-ylmethylene-2,3-dihydro-indo Ie-I- carboxylic acid tert-butyl ester as a yellow solid (Yield: 2 g, 60% ).
- E/Z-6-chloro-3-pyridin-3- ylmethylene-l,3-dihydro-indol-2-one (2.3 g, 8.96 mmol) was reacted with di-t ⁇ t-butyl- dicarbonate (2.34 g, 10.7 mmol) (Aldrich), and 4-dimethylaminopyridine (44 mg) in dichloromethane to give E/Z-6-chloro-2-o xo-3-pyridin-3-ylmethylene-2,3-dihydro-indo Ie-I- carboxylic acid tert-butyl ester as a yellow solid (Yield: 2 g, 60% ).
- racemic (2'R, 3R, 4'S, 5'S)-5',6- dichloro-2'-(5-fluoro-2-methyl-phenyl)-4'-(pyridin-3-yl) spiro[3H-indole-3,3'-piperidine]- 2,6'(lH)-dione in Example 39 (0.45 g, 0.96 mmol) was heated with DBU in toluene to give racemic (2'R,3R)-6-chloro-2'-(5-fluoro-2-methyl-phenyl)-4'-(pyridin-3-yl)-l ',3'- dihydrospiro[3H-indole-3,3'(2'H)-pyridine]-2,6'(lH)-dione as a white solid (Yield 70 mg, 17%).
- racemic (2'R, 3R, 4'S, 5'S)-5',6-dichloro-4'-(3-chloro-phenyl)-2'-[5-iodo- 2-(tetrahydro-pyran-4-yloxy)-phenyl] spiro[3H-indole-3,3 '-piperidine]-2,6'(lH)-dione in Example 43 racemic (2'S, 3R, 4'S, 5'S)-5',6-dichloro-4'-(3-chloro-phenyl)-2'-[5-iodo-2- (tetrahydro-pyran-4-yloxy)-phenyl] spiro[3H-indole-3,3'-piperidine]-2,6'(lH)-dione was obtained as the second product: a yellow solid (Yield 0.15 g, 8%).
- racemic (2'S, 3R, 4'S)-6-chloro-4'- (3-chlorophenyl)-2'-[5-Iodo-2-(tetrahydro-pyran-4-yloxy)-phenyl] spiro[3H-indole-3,3'- piperidine]-2,6'(lH)-dione (29 mg, 0.043 mmol) was reacted with trimethylsilyl acetylene (43 mg, 0.43 mmol), CuI (8 mg, 0.043 mmol), triethylamine (44 uL, 0.043 mmol) and dichlorobis(triphenylphosphine) palladium(0) (6 mg, 0.08 mmol), then treated with aqueous NaOH solution in methanol to give racemic (2'S, 3R)-6-chloro-4'-(3-chloro-phenyl)-2'-[5- e
- E/Z-6-chloro-3-(5-chloro-furan-2- ylmethylene)-l,3-dihydro-indol-2-one (5.2 g, 22.3 mmol) was reacted with di-tert-buty ⁇ - dicarbonate (4.86 g, 22.2 mmol) (Aldrich), and 4-dimethylaminopyridine (91 mg) in dichloromethane to give E/Z-6-chloro-3-(5-chloro-furan-2-ylmethylene)-2-oxo-2,3-dihydro- indole-1-carboxylic acid tert-butyl ester as a yellow solid (Yield: 6.1 g, 87%).
- racemic (2'R, 3R, 4'S, 5'S)-5',6- dichloro-4'-(5-chloro-furan-2-ylmethylene)-2'-(5-fluoro-2-methyl-phenyl) spiro[3H-indole-3,3'- piperidine]-2,6'(lH)-dione in Example 51 (0.3 g, 0.6 mmol) was heated with DBU in toluene to give racemic (2'R,3R)-6-chloro-4'-(5-chloro-furan-2-ylmethylene)-2'-(5-fluoro-2-methyl- phenyl)-l ',3'-dihydrospiro[3H-indole-3,3'(2'H)-pyridine]-2,6'(lH)-dione as a yellow solid (Yield 65 mg, 24%).
- E/Z-6-hloro-3-cyclopent-l- enylmethylene-l,3-dihydro-indol-2-one (1.13 g, 4.6 mmol) was reacted with di-tert-buty ⁇ - dicarbonate (1.1 g, 5.1 mmol) (Aldrich), and 4-dimethylaminopyridine (23 mg) in dichloromethane to give E/Z- 6-Chloro-3-cyclopent-l-enylmethylene-2-oxo-2,3-dihydro-indole- 1-carboxylic acid tert-butyl ester ester as a yellow solid (Yield: 1.5 g, 94%).
- racemic (2'R, 3R, 4'S, 5'S)-5',6- dichloro-4'-(cyclopent-l-enyl)-2'-(5-fluoro-2-methyl-phenyl) spiro[3H-indole-3,3'-piperidine]- 2,6'(lH)-dione in Example 56 (0.3 g, 0.65 mmol) was heated with DBU in toluene to give racemic (2'R,3R)-6-chloro-4'-(cyclopent-l-enyl)-2'-(5-fluoro-2-methyl-phenyl)-l ',3'- dihydrospiro[3H-indole-3,3'(2'H)-pyridine]-2,6'(lH)-dione as a yellow solid (Yield 25 mg, 9%).
- the ability of the compounds to inhibit the interaction between p53 and MDM2 proteins was measured by an HTRF (homogeneous time-resolved fluorescence) assay in which recombinant GST-tagged MDM2 binds to a peptide that resembles the MDM2-interacting region of p53 (Lane et al). Binding of GST-MDM2 protein and p53-peptide (biotinylated on its N-terminal end) is registered by the FRET (fluorescence resonance energy transfer) between Europium (Eu)-labeled anti-GST antibody and streptavidin-conjugated Allophycocyanin (APC).
- FRET fluorescence resonance energy transfer
- Test is performed in black flat-bottom 384-well plates (Costar) in a total volume of 40 uL containing:90 nM biotinylate peptide, 160 ng/ml GST-MDM2, 20 nM streptavidin-APC (PerkinElmerWallac), 2 nM Eu-labeled anti-GST-antibody (PerkinElmerWallac), 0.2% bovine serum albumin (BSA), 1 mM dithiothreitol (DTT) and 20 mM Tris-borate saline (TBS) buffer as follows: Add 10 uL of GST-MDM2 (640 ng/ml working solution) in reaction buffer to each well.
- BSA bovine serum albumin
- DTT dithiothreitol
- TBS Tris-borate saline
- Example 1CTM ( ⁇ M. 0.02%BSA)
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10706182A EP2398801A1 (en) | 2009-02-17 | 2010-02-12 | 3, 3' -spiroindolinone derivatives as anticancer agents |
CN2010800230484A CN102356082A (en) | 2009-02-17 | 2010-02-12 | 3, 3' -spiroindolinone derivatives as anticancer agents |
BRPI1008899A BRPI1008899A2 (en) | 2009-02-17 | 2010-02-12 | 3,3'-spiroindolinone derivatives as anticancer agents |
CA2751767A CA2751767A1 (en) | 2009-02-17 | 2010-02-12 | 3,3'-spiroindolinone derivatives as anticancer agents |
JP2011549573A JP2012517976A (en) | 2009-02-17 | 2010-02-12 | 3,3'-spiroindolinone derivatives as anticancer agents |
SG2011057635A SG173629A1 (en) | 2009-02-17 | 2010-02-12 | 3, 3' -spiroindolinone derivatives as anticancer agents |
AU2010215554A AU2010215554A1 (en) | 2009-02-17 | 2010-02-12 | 3, 3' -spiroindolinone derivatives as anticancer agents |
MX2011008176A MX2011008176A (en) | 2009-02-17 | 2010-02-12 | 3, 3' -spiroindolinone derivatives as anticancer agents. |
IL213920A IL213920A0 (en) | 2009-02-17 | 2011-07-04 | 3,3'-spiroindolinone derivatives as anticancer agents |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15308909P | 2009-02-17 | 2009-02-17 | |
US61/153,089 | 2009-02-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010094622A1 true WO2010094622A1 (en) | 2010-08-26 |
Family
ID=42062321
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2010/051757 WO2010094622A1 (en) | 2009-02-17 | 2010-02-12 | 3, 3' -spiroindolinone derivatives as anticancer agents |
Country Status (12)
Country | Link |
---|---|
US (1) | US8217051B2 (en) |
EP (1) | EP2398801A1 (en) |
JP (1) | JP2012517976A (en) |
KR (1) | KR20110104568A (en) |
CN (1) | CN102356082A (en) |
AU (1) | AU2010215554A1 (en) |
BR (1) | BRPI1008899A2 (en) |
CA (1) | CA2751767A1 (en) |
IL (1) | IL213920A0 (en) |
MX (1) | MX2011008176A (en) |
SG (1) | SG173629A1 (en) |
WO (1) | WO2010094622A1 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012121361A1 (en) | 2011-03-10 | 2012-09-13 | 第一三共株式会社 | Dispiropyrrolidine derivative |
WO2014038606A1 (en) | 2012-09-06 | 2014-03-13 | 第一三共株式会社 | Crystal of dispiropyrrolidine derivative |
WO2017201449A1 (en) | 2016-05-20 | 2017-11-23 | Genentech, Inc. | Protac antibody conjugates and methods of use |
WO2018074387A1 (en) | 2016-10-17 | 2018-04-26 | 第一三共株式会社 | Combination therapy method using mdm2 inhibitor and dna methyltransferase inhibitor |
US10485794B2 (en) | 2015-04-13 | 2019-11-26 | Daiichi Sankyo Company, Limited | Treatment method by combined use of MDM2 inhibitor and BTK inhibitor |
US10716790B2 (en) | 2015-02-20 | 2020-07-21 | Daiichi Sankyo Company, Limited | Method for treating cancer by combined use |
CN115772171A (en) * | 2021-09-09 | 2023-03-10 | 沈阳药科大学 | Method for synthesizing spiro [ indoline-3, 3' -piperidine ] skeleton under catalysis of monovalent gold |
WO2023056069A1 (en) | 2021-09-30 | 2023-04-06 | Angiex, Inc. | Degrader-antibody conjugates and methods of using same |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2939778C (en) * | 2007-01-31 | 2019-01-29 | Dana-Farber Cancer Institute, Inc. | Stabilized p53 peptides and uses thereof |
BRPI0809366B8 (en) | 2007-03-28 | 2021-05-25 | Harvard College | substantially alpha-helical polypeptide, method for manufacturing same, amino acid and pharmaceutical composition |
CN103282510A (en) | 2010-08-13 | 2013-09-04 | 爱勒让治疗公司 | Peptidomimetic macrocycles |
BR112014009418A2 (en) | 2011-10-18 | 2017-04-18 | Aileron Therapeutics Inc | peptidomimetic macrocycles |
US8987414B2 (en) | 2012-02-15 | 2015-03-24 | Aileron Therapeutics, Inc. | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles |
EP2822572B1 (en) | 2012-02-15 | 2020-06-10 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
CN104812384B (en) | 2012-11-01 | 2020-09-18 | 爱勒让治疗公司 | Disubstituted amino acids and methods of making and using the same |
SG11201702175YA (en) | 2014-09-24 | 2017-04-27 | Aileron Therapeutics Inc | Peptidomimetic macrocycles and formulations thereof |
CA2961258A1 (en) | 2014-09-24 | 2016-03-31 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
SG11201707750YA (en) | 2015-03-20 | 2017-10-30 | Aileron Therapeutics Inc | Peptidomimetic macrocycles and uses thereof |
CN108368161A (en) | 2015-09-10 | 2018-08-03 | 艾瑞朗医疗公司 | Peptidomimetic macrocyclic compound as MCL-1 conditioning agents |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0153818A2 (en) | 1984-02-07 | 1985-09-04 | Pfizer Inc. | 1,3-Disubstituted 2-oxindoles as analgesic and anti-inflammatory agents |
US20070213341A1 (en) | 2006-03-13 | 2007-09-13 | Li Chen | Spiroindolinone derivatives |
WO2008055812A1 (en) * | 2006-11-09 | 2008-05-15 | F. Hoffmann-La Roche Ag | Spiroindolinone derivatives |
US20080287421A1 (en) * | 2007-05-17 | 2008-11-20 | Jin-Jun Liu | 3,3-spiroindolinone derivatives |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3714473A1 (en) | 1987-04-30 | 1988-11-10 | Basf Ag | CONTINUOUS PROCESS FOR EPIMERIZING SUGAR, ESPECIALLY FROM D-ARABINOSE TO D-RIBOSE |
EP0947511A1 (en) | 1998-03-30 | 1999-10-06 | F. Hoffmann-La Roche Ag | Derivatives of phenoxy acetic acid and of phenoxymethyl tetrazole having antitumor activity |
WO1999065494A1 (en) * | 1998-06-15 | 1999-12-23 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
CN1361779A (en) | 1999-07-21 | 2002-07-31 | 阿斯特拉曾尼卡有限公司 | New compounds |
CN101160314B (en) | 2005-02-22 | 2012-05-23 | 密执安州立大学董事会 | Small molecule inhibitors of mdm2 and the uses thereof |
EP1996591B1 (en) * | 2006-03-13 | 2011-01-12 | F. Hoffmann-La Roche AG | Spiroindolinone derivatives |
US7495007B2 (en) | 2006-03-13 | 2009-02-24 | Hoffmann-La Roche Inc. | Spiroindolinone derivatives |
WO2008005268A1 (en) | 2006-06-30 | 2008-01-10 | Schering Corporation | Substituted piperidines that increase p53 activity and the uses thereof |
WO2008060789A2 (en) * | 2006-10-12 | 2008-05-22 | Xenon Pharmaceuticals Inc. | Use of spiro-oxindole compounds as therapeutic agents |
WO2008080822A1 (en) | 2006-12-29 | 2008-07-10 | F. Hoffmann-La Roche Ag | Epimerization methodologies for recovering stereo isomers in high yield and purity |
US7834179B2 (en) * | 2007-05-23 | 2010-11-16 | Hoffmann-La Roche Inc. | Spiroindolinone derivatives |
US7776875B2 (en) | 2007-12-19 | 2010-08-17 | Hoffman-La Roche Inc. | Spiroindolinone derivatives |
-
2010
- 2010-01-07 US US12/683,468 patent/US8217051B2/en not_active Expired - Fee Related
- 2010-02-12 MX MX2011008176A patent/MX2011008176A/en not_active Application Discontinuation
- 2010-02-12 EP EP10706182A patent/EP2398801A1/en not_active Withdrawn
- 2010-02-12 KR KR1020117019019A patent/KR20110104568A/en not_active Application Discontinuation
- 2010-02-12 AU AU2010215554A patent/AU2010215554A1/en not_active Abandoned
- 2010-02-12 CA CA2751767A patent/CA2751767A1/en not_active Abandoned
- 2010-02-12 JP JP2011549573A patent/JP2012517976A/en active Pending
- 2010-02-12 BR BRPI1008899A patent/BRPI1008899A2/en not_active IP Right Cessation
- 2010-02-12 WO PCT/EP2010/051757 patent/WO2010094622A1/en active Application Filing
- 2010-02-12 CN CN2010800230484A patent/CN102356082A/en active Pending
- 2010-02-12 SG SG2011057635A patent/SG173629A1/en unknown
-
2011
- 2011-07-04 IL IL213920A patent/IL213920A0/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0153818A2 (en) | 1984-02-07 | 1985-09-04 | Pfizer Inc. | 1,3-Disubstituted 2-oxindoles as analgesic and anti-inflammatory agents |
US20070213341A1 (en) | 2006-03-13 | 2007-09-13 | Li Chen | Spiroindolinone derivatives |
WO2008055812A1 (en) * | 2006-11-09 | 2008-05-15 | F. Hoffmann-La Roche Ag | Spiroindolinone derivatives |
US20080287421A1 (en) * | 2007-05-17 | 2008-11-20 | Jin-Jun Liu | 3,3-spiroindolinone derivatives |
Non-Patent Citations (5)
Title |
---|
ANSEL ET AL.: "Pharmaceutical Dosage Forms and Drug Delivery Systems", pages: 196,1456 - 1457 |
J. AM. CHEM. SOC., 1999 |
KRAYNACK, E. A.; DALGARD, J. E.; GAETA, F. C. A., TETRAHEDRON LETTERS, vol. 39, 1998, pages 7679 - 7682 |
SUTO, M.J. ET AL., J MED. CHEM, 1991, pages 2484 |
TETRAHEDRON, 1995, pages 11021 |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012121361A1 (en) | 2011-03-10 | 2012-09-13 | 第一三共株式会社 | Dispiropyrrolidine derivative |
US8629133B2 (en) | 2011-03-10 | 2014-01-14 | Daiichi Sankyo Company, Limited | Dispiropyrrolidine derivatives |
US9745315B2 (en) | 2012-09-06 | 2017-08-29 | Daiichi Sankyo Company, Limited | Crystals of dispiropyrrolidine derivatives |
US10030030B2 (en) | 2012-09-06 | 2018-07-24 | Daiichi Sankyo Company, Limited | Crystals of dispiropyrrolidine derivatives |
US9359368B2 (en) | 2012-09-06 | 2016-06-07 | Daiichi Sankyo Company, Limited | Crystals of dispiropyrrolidine derivatives |
US9540386B2 (en) | 2012-09-06 | 2017-01-10 | Daiichi Sankyo Company, Limited | Crystals of dispiropyrrolidine derivatives |
US9718830B2 (en) | 2012-09-06 | 2017-08-01 | Daiichi Sankyo Company, Limited | Crystals of dispiropyrrolidine derivatives |
US9718831B2 (en) | 2012-09-06 | 2017-08-01 | Daiichi Sankyo Company, Limited | Crystals of dispiropyrrolidine derivatives |
WO2014038606A1 (en) | 2012-09-06 | 2014-03-13 | 第一三共株式会社 | Crystal of dispiropyrrolidine derivative |
US9884871B2 (en) | 2012-09-06 | 2018-02-06 | Daiichi Sankyo Company, Limited | Crystals of dispiropyrrolidine derivatives |
KR20150048140A (en) | 2012-09-06 | 2015-05-06 | 다이이찌 산쿄 가부시키가이샤 | Crystal of dispiropyrrolidine derivative |
US10023578B2 (en) | 2012-09-06 | 2018-07-17 | Daiichi Sankyo Company, Limited | Crystals of dispiropyrrolidine derivatives |
US10716790B2 (en) | 2015-02-20 | 2020-07-21 | Daiichi Sankyo Company, Limited | Method for treating cancer by combined use |
US10485794B2 (en) | 2015-04-13 | 2019-11-26 | Daiichi Sankyo Company, Limited | Treatment method by combined use of MDM2 inhibitor and BTK inhibitor |
WO2017201449A1 (en) | 2016-05-20 | 2017-11-23 | Genentech, Inc. | Protac antibody conjugates and methods of use |
KR20190068544A (en) | 2016-10-17 | 2019-06-18 | 다이이찌 산쿄 가부시키가이샤 | Combination treatment of MDM2 inhibitor with DNA methyltransferase inhibitor |
WO2018074387A1 (en) | 2016-10-17 | 2018-04-26 | 第一三共株式会社 | Combination therapy method using mdm2 inhibitor and dna methyltransferase inhibitor |
CN115772171A (en) * | 2021-09-09 | 2023-03-10 | 沈阳药科大学 | Method for synthesizing spiro [ indoline-3, 3' -piperidine ] skeleton under catalysis of monovalent gold |
WO2023056069A1 (en) | 2021-09-30 | 2023-04-06 | Angiex, Inc. | Degrader-antibody conjugates and methods of using same |
Also Published As
Publication number | Publication date |
---|---|
SG173629A1 (en) | 2011-09-29 |
MX2011008176A (en) | 2011-08-17 |
EP2398801A1 (en) | 2011-12-28 |
BRPI1008899A2 (en) | 2018-03-13 |
IL213920A0 (en) | 2011-07-31 |
JP2012517976A (en) | 2012-08-09 |
CA2751767A1 (en) | 2010-08-26 |
US8217051B2 (en) | 2012-07-10 |
AU2010215554A1 (en) | 2011-07-28 |
US20100210674A1 (en) | 2010-08-19 |
CN102356082A (en) | 2012-02-15 |
KR20110104568A (en) | 2011-09-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8217051B2 (en) | Spiroindolinone derivatives | |
EP2152714B1 (en) | SPIROINDOLINONE DERIVATIVES AS MDM2-p53 INHIBITORS | |
US8217044B2 (en) | Spiroindolinone pyrrolidines | |
US8076482B2 (en) | 3,3′-spiroindolinone derivatives | |
EP2089360B1 (en) | Spiroindolinone derivatives | |
EP1996591B1 (en) | Spiroindolinone derivatives | |
US7928233B2 (en) | Spiroindolinone pyridine derivatives | |
CA2787304A1 (en) | Substituted spiroindolinones | |
WO2010084097A1 (en) | Spiroindolinone derivative prodrugs | |
US20130053410A1 (en) | Substituted heteroaryl 2',3',7',7a'-tetrahydrospiro[pyrrole-3,6'-pyrrolo[1,2-c]imidazole]-1',2(1h,5'h)-dione | |
US20080188506A1 (en) | Spiroindolinone derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080023048.4 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10706182 Country of ref document: EP Kind code of ref document: A1 |
|
REEP | Request for entry into the european phase |
Ref document number: 2010706182 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010706182 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010215554 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2010215554 Country of ref document: AU Date of ref document: 20100212 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2011/008176 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2751767 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 20117019019 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011549573 Country of ref document: JP Ref document number: 5894/CHENP/2011 Country of ref document: IN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: PI1008899 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: PI1008899 Country of ref document: BR Kind code of ref document: A2 Effective date: 20110817 |